Compare DKI & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | CELZ |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Hong Kong | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 7.8M |
| IPO Year | N/A | 2008 |
| Metric | DKI | CELZ |
|---|---|---|
| Price | $4.80 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.1K | 59.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $1.50 |
| 52 Week High | $11.80 | $6.25 |
| Indicator | DKI | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 18.86 |
| Support Level | $0.39 | N/A |
| Resistance Level | $6.80 | $2.42 |
| Average True Range (ATR) | 0.80 | 0.19 |
| MACD | -0.22 | -0.07 |
| Stochastic Oscillator | 16.15 | 3.62 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.